LKC Technologies Announces Acquisition by AMETEK, Strengthening Its Long-Term Commitment to ECPs

Published on February 19, 2026
GERMANTOWN, Md.—LKC Technologies, a leader in functional retinal testing using electroretinography (ERG), announced it has been acquired by AMETEK, Inc. (NYSE: AME), a global provider of industrial technology solutions. LKC Technologies said that the acquisition reflects the company’s continued growth, strong market adoption, and long-term commitment to supporting eyecare professionals worldwide. Over the past several years, LKC Technologies has experienced strong, sustained growth driven by the trust and engagement of ECPs who rely on the RETeval ERG, a handheld device that measures electrical activity in the eye to evaluate retinal function and detect disease, the company added.
Continue reading on website
Other news

Outlook Therapeutics Reports Q1 Fiscal Year 2026 Financial Results

February 19, 2026
ISELIN, N.J.—Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on improving the standard of care for bevacizumab in treating retina diseases, has announced its financial results for the first quarter of fiscal year 2026, which concluded on December 31, 2025. The company reported a net loss of $23.1 million for the quarter, which represents a decline compared with the $

FDA Approves Expanded Age Range for STAAR Surgical’s EVO ICL for Vision Correction

February 19, 2026
LAKE FOREST, Calif.—STAAR Surgical Company, a leading developer of phakic intraocular lenses with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, has announced that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for EVO/EVO+ Visian ICL for patients aged 21 to 60 years old, up from the previous approval for ages 21-45. This approva